SEC Form 4 · accession 0001104659-18-058320
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Aoife Brennan
Director
Period of report
Sep 21, 2018
Accepted (ET)
Sep 25, 2018 · 9:20 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $16.36 | Sep 21, 2018 | A | 25,000 | A | — | Sep 21, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1On September 21, 2018, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock. The option will vest and become exercisable in three equal installments on each of September 21, 2019, September 21, 2020 and September 21, 2021.